KLHL2 Activators are a specialized group of chemicals that target the intricate biochemical pathways involving the protein Kelch-like protein 2, encoded by the KLHL2 gene. This protein is part of the BTB-Kelch superfamily, playing a critical role in ubiquitination processes, which are essential for protein degradation and regulation within the cell. The activators of KLHL2 engage with the protein's function by stabilizing its structure or enhancing its interaction with E3 ubiquitin ligase complexes, leading to a more efficient ubiquitination process. These compounds exhibit their effect by binding to specific domains within KLHL2, promoting its ability to target substrates for ubiquitination. The result of such activation is a nuanced regulation of protein turnover, which is a pivotal process in maintaining cellular homeostasis. Furthermore, these activators can indirectly influence the activity of KLHL2 by modulating the cellular environment to favor the protein's stability and interaction with its partners. For instance, certain activators may increase the availability of molecular chaperones that assist in the proper folding of KLHL2, thereby ensuring its functional conformation is maintained for optimal performance within the ubiquitin-proteasome pathway.
In addition to stabilizing KLHL2's structure, some activators may enhance the protein's functionality by affecting the ATPase activity that is indirectly associated with its function. By increasing cellular ATP levels, these compounds can amplify the energy-dependent steps of the ubiquitination cascade that KLHL2 is part of, leading to a more vigorous tagging of proteins for degradation. The upsurge in ubiquitination directly correlates with an upregulated activity of KLHL2, as it is more frequently called upon to fulfill its role within the cell. This heightened activity is paramount in regulating various cellular processes, such as signal transduction, cell cycle progression, and apoptosis, which are all influenced by the ubiquitination status of key regulatory proteins. KLHL2 Activators, therefore, play a critical role in fine-tuning these processes by ensuring that KLHL2 is active and capable of carrying out its essential duties in the proteasomal degradation machinery, thereby upholding the cellular equilibrium and adapting to the varying demands of the intracellular milieu.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing cAMP levels in cells. Elevated cAMP activates PKA, which can phosphorylate KLHL2, leading to its enhanced functional activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate substrates including KLHL2, thereby potentially enhancing KLHL2's role in protein ubiquitination. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin increases intracellular calcium concentration, which can activate calcium/calmodulin-dependent protein kinases that are capable of phosphorylating KLHL2, thus enhancing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which leads to a decrease in AKT phosphorylation. This shift in signaling may enhance KLHL2 activity by reducing negative feedback regulation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that may reduce competitive phosphorylation, potentially allowing for enhanced activation of KLHL2 by other kinases. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, altering the signaling dynamics and potentially enhancing KLHL2-mediated ubiquitination by reducing competing signaling activities. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate activates sphingosine kinase, which may promote signaling pathways that enhance the activity of KLHL2. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin raises intracellular calcium levels, which may stimulate KLHL2 activity through calcium-dependent signaling pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein inhibits tyrosine kinases, which may reduce phosphorylation-based inhibition and enhance the ubiquitin ligase activity of KLHL2. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that could, paradoxically, enhance KLHL2 activity by inhibiting kinases that negatively regulate KLHL2. | ||||||